论文部分内容阅读
目的观察多西他赛联合顺铂治疗非小细胞肺癌的近期疗效和安全性。方法经病理组织学或细胞学证实非小细胞肺癌患者40例,均给予多西他赛联合顺铂方案化疗,21d为1个周期。每周期评价不良反应,2个周期后评价近期疗效。结果 40例患者均完成2个周期治疗,部分缓解12例,稳定18例,进展10例,近期有效率为30%,临床获益率为75%;治疗过程中未发生治疗相关性死亡,发生骨髓抑制27例,血红蛋白减少15例,血小板减少8例,胃肠道反应29例,脱发33例,肝功能异常6例,肾功能异常2例,2例因出现Ⅳ级粒细胞减少2次停止治疗,4例因经济原因放弃治疗,余经治疗后好转。结论多西他赛联合顺铂治疗非小细胞肺癌临床受益良好,不良反应可耐受。
Objective To observe the short-term efficacy and safety of docetaxel combined with cisplatin in the treatment of non-small cell lung cancer. Methods Forty cases of non-small cell lung cancer (NSCLC) confirmed by histopathology and cytology were given docetaxel combined with cisplatin chemotherapy for 21 days. Adverse reactions were evaluated every cycle, and the short-term efficacy was evaluated after 2 cycles. Results 40 patients completed two cycles of treatment, partial response in 12 cases, stable in 18 cases, progress in 10 cases, the recent effective rate was 30%, the clinical benefit rate was 75%; no treatment-related deaths occurred during the treatment occurred Myelosuppression in 27 cases, hemoglobin reduction in 15 cases, thrombocytopenia in 8 cases, gastrointestinal reactions in 29 cases, hair loss in 33 cases, 6 cases of abnormal liver function, renal dysfunction in 2 cases, 2 cases of grade Ⅳ neutropenia stopped 2 times Treatment, 4 cases for economic reasons to give up treatment, more than after treatment improved. Conclusion Docetaxel combined with cisplatin in the treatment of non-small cell lung cancer has a good clinical benefit, adverse reactions can be tolerated.